Business Section: Investing Ideas
While there is still no flu panacea of sorts, the morphing disease has kept things interesting for biotech and pharmaceutical companies in the vaccine business.
Quadrivalent solutions may see better profit margins in a limited market of about 130-150 million Americans (less than half) each year. For big firms, flu vaccines are a minor source of revenue. For example, The business brings in about $718 mil for Novartis, less than 2% of yearly revenue.
But small companies have taken the unpredictable into their hands, on the lookout for better, more stable solutions to influenza. Think of the vaccine shortage in 2004 or the 2009 “swine” flue pandemic. These are ongoing issues that don’t have reliable protective measures.Major flu vaccine manufacturers: 1. AstraZeneca PLC (AZN, Earnings, Analysts, Financials): Develops, and commercializes prescription medicines for cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory and inflammation diseases worldwide. Market cap at $57.66B, most recent closing price at $46.31. 2. GlaxoSmithKline plc (GSK, Earnings, Analysts, Financials): Engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. Market cap at $105.01B, most recent closing price at $42.73. 3. Sanofi (SNY, Earnings, Analysts, Financials): Engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. Market cap at $118.38B, most recent closing price at $44.66. 4. Novartis AG (NVS, Earnings, Analysts, Financials): Engages in the research, development, manufacture, and marketing of healthcare products worldwide. Market cap at $164.35B, most recent closing price at $60.73. Companies developing a universal vaccine: 5. Dynavax Technologies Corporation (DVAX, Earnings, Analysts, Financials): Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. Market cap at $514.68M, most recent closing price at $2.88.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV